Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is the decrease in arterial pressure the sole factor for reduction of left ventricular hypertrophy?

R E Schmieder1, F H Messerli

  • 1Department of Medicine, University of Erlangen, Nümberg, Germany.

The American Journal of Medicine
|April 27, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urocortin 2 - a protective effect in hypertension?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

More SPRINT controversy.

Journal of internal medicine·2017
Same author

Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?

Hipertension y riesgo vascular·2015
Same author

Cardioprotection with beta-blockers: myths, facts and Pascal's wager.

Journal of internal medicine·2009
Same author

Beta-blockers as fourth-line therapy for hypertension: stay the course.

International journal of clinical practice·2009
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Left ventricular hypertrophy (LVH) is a key prognostic factor. This study questions if reducing LVH is a primary goal of hypertension treatment and explores blood pressure-independent factors influencing LVH reduction.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Pathophysiology

Background:

  • Left ventricular hypertrophy (LVH) is recognized as a significant prognostic indicator in cardiovascular disease.
  • Antihypertensive therapy aims to manage blood pressure, but its impact on LVH requires further investigation.

Purpose of the Study:

  • To evaluate whether reducing LVH is a desirable therapeutic goal in antihypertensive treatment.
  • To determine if decreased arterial pressure is the sole determinant for LVH reduction.

Main Methods:

  • Analysis of pathogenic mechanisms underlying LVH development.
  • Review of studies examining LVH reduction with various antihypertensive agents.

Main Results:

  • Evidence suggests multiple interacting factors contribute to LVH pathogenesis.

Related Experiment Videos

  • Disparate LVH reduction rates across different antihypertensive drugs indicate blood pressure-independent influences.

    • Conclusions:

    • LVH reduction may be a crucial therapeutic objective beyond mere blood pressure control.
    • Blood pressure-independent mechanisms significantly influence the regression of LVH in hypertensive patients.